# US 2017/0281549 A1 · Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281549 A1
- Document ID: US20170281549A1
- Status: Published application
- Kind: A1
- Application number: 15/629,636
- Filed: 2017-06-21
- Published: 2017-10-05
- Earliest claimed: 2005-09-14
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Keith A. Oberg; Joseph Sulner; Marshall L. Grant
- Web page: https://patentgrep.com/patent/US20170281549A1

## CPC

- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/5052: {Proteins, e.g. albumin}
- A61K 9/5089: {Processes}
- A61K 38/13: Cyclosporins
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61K 38/26: Glucagons
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 5/18: of the parathyroid hormones
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.

## Claims

### Claim 1

A method for coating a crystalline microparticle with an active agent in a suspension, the method comprising the following sequential steps:
(i) dissolving the active agent in a solvent;
(ii) obtaining a crystalline diketopiperazine microparticle wherein the crystalline diketopiperazine microparticle does not comprise an active agent;
(iii) forming a suspension comprising the crystalline diketopiperazine microparticle, the active agent, and the solvent;
(iv) increasing pH of the suspension from about pH 3.0 to between about pH 4.4 and about pH 5;
(v) adsorbing the active agent onto a surface of the crystalline diketopiperazine microparticle to provide a coating of the active agent on the crystalline diketopiperazine microparticle;
(vi) removing or exchanging the solvent after step (v).

### Claim 2 (depends on 1)

The method of claim 1, wherein the active agent is an insulin or an insulin analog.

### Claim 3 (depends on 1)

The method of claim 1, wherein the resulting microparticle comprises about 9% to about 12% active agent by weight.

### Claim 4 (depends on 1)

The method of claim 1, wherein the core of the crystalline diketopiperazine microparticle microparticle comprises polysorbate 80.

### Claim 5 (depends on 4)

The method of claim 4, wherein the crystalline diketopiperazine microparticle comprises at least 0.7% polysorbate 80 by weight.

### Claim 6 (depends on 5)

The method of claim 5, wherein crystalline diketopiperazine microparticle comprises between 0.7% and 3.5% polysorbate 80 by weight.

### Claim 7 (depends on 1)

The method of claim 1, wherein the active agent coating on the resulting microparticle is predominantly a monolayer.

### Claim 8 (depends on 1)

The method of claim 1, wherein at least a portion of the active agent is electrostatically bound to the crystalline diketopiperazine microparticle.

### Claim 9 (depends on 8)

The method of claim 8, wherein a majority of the active agent coating is bound to the crystalline diketopiperazine microparticle.

### Claim 10 (depends on 1)

The method of claim 1, wherein the active agent coating is about 11.4% of the total weight of the microparticle.

### Claim 11 (depends on 1)

The method of claim 1, wherein the active agent comprises at least one of a peptide, polypeptide, or a protein.

### Claim 12 (depends on 1)

The mthod of claim 1, wherein the active agent comprises at least one of insulin, parathyroid hormone, growth hormone, ghrelin, GLP-1, anti-SSZ241-49 monoclonal antibody, or anti-MOPC-21 monoclonal antibody.

### Claim 13 (depends on 1)

The method of claim 1, wherein the active agent comprises at least one of insulin, an insulin analog, growth hormone, parathyroid hormone, ghrelin, granulocyte macrophage colony stimulating factor (GM-CSF), glucagon-like peptide 1 (GLP-1), Texas Red, alkynes, cyclosporins, clopiogrel and PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), or antibodies and fragments thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the antibodies or fragments thereof include humanized or chimeric antibodies.

### Claim 15 (depends on 14)

The method of claim 14, wherein the humanized or chimeric antibodies are selected from F(ab); F(ab)2; single-chain antibody alone or fused to other polypeptides; therapeutic or diagnostic monoclonal antibodies to cancer antigens, cytokines, infectious agents, inflammatory mediators, hormones, and cell surface antigens.

### Claim 16 (depends on 19)

The method of claim 19, wherein the antibodies to tumor antigens are selected from anti-SSX-241-49, anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, and anti-MOPC-21.
